⌕
Exelixis · EXEL · Nasdaq
Tenet 74 · Solid
Compare
$68.50+2.09%At closeTenet 74 · Solid
$68.50+1.40 (+2.09%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Exelixis (EXEL) Stock

Exelixis (EXEL) closed at $68.50 on Nov 17, 2026; its Tenet Score is 74 of 100 against 340 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

5 figures withheld by our checks. Each blank figure names its reason.

Key stats

Close
$68.50
Nov 17, 2026
Market cap
$16.6B
share price × the latest quarter's diluted weighted-average share count (vendor)
P/E
20.2×
TTM through Jul 3, 2026 · as of close, Nov 16, 2026
52-week range
39.71 – 73.69
low → high · as of close, Nov 16, 2026
Tenet Score
74/100
Solid · 340 Healthcare peers

Industry: Drugs

Exelixis Inc scores 74/100. Solid. Strongest on growth and quality, trading at 20× earnings versus 340 Healthcare peers.

Tenet Score · vs sector

n=340
74/ 100
Solid
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
62
Quality
82
Health
68
Growth
86

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
ValueCQualityBHealthCGrowthBMomentumB
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/B
9.0×
Jul 3, 2026 balance sheet
P/S
6.8×
price to sales, TTM through Jul 3, 2026 · as of close, Nov 16, 2026
ROE
44%
TTM through Jul 3, 2026
Operating margin
37.6%
fiscal 2025, before interest and tax
Net margin
35.3%
TTM through Jul 3, 2026
Current ratio
3.46
Jul 3, 2026 balance sheet
Net debt / EBITDA
−0.8×
TTM through Jul 3, 2026
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.
Div yield
—
no yield on file

The whole report, at a glance · every card is a live peek, click any to open the section

About Exelixis Inc

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients wi…

Composite computed Nov 16, 2026 · peer basis: Healthcare (n=340) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 254 US ETFs · top wrappers by weightSee all ETFs holding EXEL →

Similar-sized companies in Drugs

The 10 companies in this industry closest in market cap, as of Nov 16, 2026.

What sector and industry is Exelixis in?

Exelixis is in the Healthcare sector and the Drugs industry.

What is Exelixis' Tenet Score?

Exelixis' Tenet Score is 74 out of 100, ranked against 340 Healthcare peers as of Nov 16, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.